Gordis Epidemiology: Comprehensive Review (Chapters 14–20)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/66

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering epidemiologic principles of causality, bias and confounding, gene-environment interactions, healthcare evaluation, screening assessment, public policy risk analysis, and ethics based on Gordis Epidemiology.

67 Terms

1
New cards

Etiology

The cause, set of causes, or manner of causation of a disease or condition, including the investigation of the attribution of cause.

2
New cards
<p>Sequence of Epidemiologic Study Designs</p>

Sequence of Epidemiologic Study Designs

The typical observational pathway used to investigate disease causation, beginning with clinical observations, followed by analysis of available data, case-control studies, cohort studies, and culminating in randomized trials.

3
New cards

Spurious Association

A false observed association between an exposure and a disease that is not real for the characteristic under study, often arising because a third confounding factor is unmeasured or not discounted.

4
New cards
<p>Direct vs. Indirect Causal Relationships</p>

Direct vs. Indirect Causal Relationships

The distinction between a factor immediately causing disease without intermediary steps (direct) versus a factor acting through one or more intermediate biological steps or cofactors before disease develops (indirect, the common pathway in human chronic disease).

5
New cards

Necessary and Sufficient Causal Relationship

A causal model where disease never develops in the absence of the factor, and always develops in its presence; rare and typically direct.

6
New cards

Necessary but Not Sufficient Causal Relationship

A causal model where each factor is required for disease development but cannot produce it alone, necessitating multiple factors operating in a specific temporal sequence (e.g., initiation and promotion in carcinogenesis).

7
New cards

Sufficient but Not Necessary Causal Relationship

A causal model where a specific factor alone can produce the disease, but other factors acting independently can also produce the exact same condition (e.g., radiation or benzene independently leading to leukemia).

8
New cards

Neither Sufficient nor Necessary Causal Relationship

A causal model where a factor cannot cause disease on its own and is not mandatory for disease development, representing non-overlapping risk factor clusters typical of chronic diseases like coronary heart disease (CHDCHD).

9
New cards

Temporality

A causal guideline dictating that exposure to the hypothesized causal factor must precede the biologic onset and development of the disease in time.

10
New cards

Strength of Association

The magnitude of the relationship between an exposure and an outcome, measured by relative risks (RRRR), odds ratios (OROR), risk differences (RDRD), or correlation coefficients (rr), where larger magnitudes are more likely to represent true causation.

11
New cards

Dose-Response Relationship

A pattern where increasing levels, amounts, or durations of an exposure correspond to a stepwise increase in the risk of disease, requiring evaluation of at least three exposure levels.

12
New cards

Biologic Plausibility

The coherence of an observed epidemiological association with existing biological, physiological, and mechanistic scientific knowledge.

13
New cards

Cessation of Exposure

A causal criterion demonstrated when the risk of developing a disease declines following the reduction or complete elimination of exposure to the factor.

14
New cards

Mill's Canons (in Epidemiology)

The six condensed guidelines derived from J.S. Mill and Sir Austin Bradford Hill used to evaluate causal inference: Temporality, Consistency, Strength of Association, Dose-Response, Plausibility, and Independence.

15
New cards

Bias

Any systematic error in the design, conduct, or analysis of a study that results in a mistaken or distorted estimate of an exposure's effect on disease risk.

16
New cards

Selection Bias

Systematic error introduced when study subjects or data are selected non-randomly such that the study sample fails to represent the target population of interest, distorting internal and external validity.

17
New cards

Information Bias

Any systematic difference from the truth arising from flaws in the collection, recall, recording, or handling of data regarding exposures and/or disease outcomes.

18
New cards

Differential Misclassification

A classification error occurring at different rates across study groups (e.g., recall differing between cases and controls), leading to a systematic skew in the estimated effect.

19
New cards

Nondifferential Misclassification

A classification error occurring equally across all study groups due to imperfect data collection methods, which adds variability and biases the study results toward the null.

20
New cards

Confounder

A third factor (XX) in an exposure-disease study that is a known risk factor for the disease and is associated with the exposure, but is not a biological result of the exposure.

21
New cards

Stratification

An analytical technique used to control for confounding by evaluating the exposure-disease relationship separately within distinct, homogeneous strata of the potential confounding variable.

22
New cards

Interaction (Effect Modification)

A phenomenon occurring when the incidence rate of disease in the presence of two or more risk factors differs from the incidence rate expected to result from their individual effects.

23
New cards

Additive Interaction Model

An interaction model assessed using attributable risks (ARAR), in which the excess risk of disease in the presence of two factors exceeds the sum of the excess risks of each factor operating alone.

24
New cards

Multiplicative Interaction Model

An interaction model assessed using relative risks (RRRR), in which the combined relative risk of two factors exceeds the mathematical product of the relative risks of the individual factors.

25
New cards

Genotype

The complete genetic constitution and underlying DNA make-up of an individual organism.

26
New cards

Phenotype

The observable physical, biochemical, or clinical traits of an individual resulting from the interaction of their genotype with environmental influences.

27
New cards

Allele

One of two or more alternative functional forms of a gene that arise via mutation and occupy the identical physical locus on a chromosome.

28
New cards
<p>Epidemiologic Triad</p>

Epidemiologic Triad

The traditional epidemiologic model representing the complex interplay among the Host, Agent, and Environment, often mediated by an intermediate Vector, necessary for disease transmission.

29
New cards

Monozygotic (MZ) Twins

Identical twins originating from a single fertilized ovum who share 100%100\% of their genetic material.

30
New cards

Dizygotic (DZ) Twins

Fraternal twins developing from two separately fertilized ova who share on average 50%50\% of their genetic material, comparable to ordinary biological siblings.

31
New cards

Concordance Rate (Twin Studies)

The probability that both members of a twin pair express a disease given that at least one twin has it, calculated as CR=aa+b+cCR = \frac{a}{a + b + c}.

32
New cards

Discordance Rate (Twin Studies)

The proportion of disease-affected twin pairs in which only one member of the pair possesses the condition, calculated as DR=b+ca+b+cDR = \frac{b + c}{a + b + c}.

33
New cards

Assortative Mating

Nonrandom mating in which individuals select marriage or reproductive partners who possess similar physical, behavioral, or phenotypic characteristics to themselves.

34
New cards

Migrant Studies

Epidemiologic study designs that assess the relative contributions of genetic versus environmental factors by observing changes in disease rates among populations migrating from an ancestral environment to a new host environment.

35
New cards

Structure (Health Services)

The physical facilities, specialized equipment, personnel, and financial resources designated for the delivery of medical and public health services.

36
New cards

Process (Health Services)

The operational activities, medical procedures, clinical interventions, and preventive services administered during patient care.

37
New cards

Outcome (Health Services)

The measurable changes in health status—such as morbidity, mortality, functioning, dependency, or quality of life—that result from the healthcare interventions provided.

38
New cards

Efficacy

The measure of improvement or beneficial effect produced by a healthcare intervention under ideal conditions among patients who strictly comply with or adhere to the prescribed protocol.

39
New cards

Effectiveness

The measure of benefit or clinical improvement attained when an intervention is implemented across the broader target population under real-world conditions, regardless of compliance.

40
New cards

Efficiency

The cost-to-benefit ratio of a healthcare program or intervention, where lower ratios signify superior efficacy or effectiveness achieved relative to the resources expended.

41
New cards

Outcomes Research

Comparative studies examining the impacts of differing healthcare interventions, organizational models, or reimbursement schemes on clinical and economic endpoints using aggregate data.

42
New cards

Avoidable Mortality

An epidemiologic index measuring premature deaths that could have been prevented through timely public health initiatives and primary prevention interventions before disease onset.

43
New cards

Sentinel Event

An unanticipated, serious occurrence in a healthcare facility resulting in death or profound physical or psychological harm unrelated to the natural history of the patient's illness.

44
New cards

Preclinical Phase

The biological stage in the natural history of disease extending from initial biological onset to the appearance of first clinical signs and symptoms.

45
New cards

Clinical Phase

The stage in the natural history of disease marked by the presentation of symptoms and signs, during which diagnosis and therapy occur, culminating in cure, control, or death.

46
New cards
<p>Lead Time</p>

Lead Time

The time interval by which a disease diagnosis is advanced via early screening detection as compared to the usual time diagnosis would have occurred based on symptoms.

47
New cards
<p>Critical Point</p>

Critical Point

A pivotal milestone in the natural history of a disease before which medical therapy is more curable or less damaging, and after which treatment becomes ineffective.

48
New cards

Referral Bias (Volunteer Bias)

A systematic error in screening evaluations arising because volunteers typically possess healthier baseline lifestyles and adhere more diligently to medical recommendations than non-volunteers.

49
New cards

Length-Biased Sampling (Prognostic Selection)

A screening bias occurring because screening modalities preferentially identify indolent, slow-progressing cases with prolonged preclinical intervals rather than aggressive, rapid cases.

50
New cards

Lead-Time Bias

An artificial lengthening of calculated survival time produced simply by diagnosing disease earlier via screening without actually altering the biological time of death.

51
New cards

Overdiagnosis Bias

An overestimation of screening benefit caused by identifying subclinical lesions or indolent diseases that would never have manifested clinically or caused death during the subject's lifetime.

52
New cards

Macroenvironmental Exposure

Ubiquitous environmental factors affecting entire communities or populations (such as ambient air pollutants or drinking water supplies) that are primarily controllable via policy and legislation.

53
New cards

Microenvironmental Exposure

Specific personal factors affecting an individual directly (including diet, personal cigarette smoking, and individual alcohol intake) that rely on lifestyle modifications and behavioral change.

54
New cards

Risk Assessment

The scientific characterization and systematic qualitative and quantitative evaluation of adverse health effects resulting from human exposures to hazardous environmental agents.

55
New cards

Hazard Identification

The initial step in the risk assessment process that determines whether a specific environmental agent is causally linked to particular adverse health outcomes.

56
New cards

Dose-Response Assessment

The risk assessment step evaluating the mathematical relationship between the dose of an exposure administered or received and the incidence or probability of adverse human health outcomes.

57
New cards

Exposure Assessment

The step in risk assessment determining the magnitude, duration, frequency, and pathways of human contact with an agent, either before or after regulatory controls.

58
New cards

Risk Characterization

The integrative phase of risk assessment synthesizing hazard identification, dose-response, and exposure data to estimate the actual incidence of health effects in a given population along with attendant uncertainties.

59
New cards
<p>Biological Dosing Continuum</p>

Biological Dosing Continuum

The physiological pathway tracing a hazardous substance through successive biological stages: the initial exposure dose in the environment, the absorbed dose internalized in the body, and the ultimate target tissue dose reaching susceptible organs.

60
New cards

Risk Management

The regulatory and political decision-making process that weighs public health, economic, social, and technological consequences to select and implement strategies controlling hazardous exposures.

61
New cards

Publication Bias

The systematic tendency in scientific literature where studies reporting statistically significant 'positive' findings are published, while studies with non-significant 'negative' results are withheld from publication.

62
New cards

Informed Consent

An ethical process rooted in personal autonomy where investigators or clinicians fully disclose the potential risks, benefits, and alternatives of a study or intervention to prospective subjects prior to participation.

63
New cards

Beneficence

The fundamental ethical principle obligating investigators to act in the best interests of research participants, promoting their welfare and legitimate health goals.

64
New cards

Nonmaleficence

The core bioethical imperative requiring physicians and epidemiologic researchers to 'do no harm' to patients and human research subjects.

65
New cards

Principle of Utility

The ethical rule stating that public health interventions must generate the greatest overall net benefit while conscientiously balancing those benefits against costs, harms, and individual burdens.

66
New cards

Ethnicity

A complex social construct referring to shared social backgrounds, cultural traditions, language, nationality, or religious beliefs that are transmitted across generations to form group identity.

67
New cards

Conflict of Interest (Epidemiologic Research)

A situation where secondary financial, institutional, or political interests (such as commercial industry profits or government agendas) have the potential to compromise or bias the design, execution, or publication of research findings.